Cytomegalovirus infection and ganciclovir resistance caused by UL97 mutations in pediatric transplant recipients

Transplant Infectious Disease

Volumn 14, Issue 6, 2012, Pages 611-617

  Kim, Y J ^a,b,c   Boeckh, M ^a,d   Cook, L ^a,d   Stempel, H ^b   Jerome, K R ^a,d   Boucek, R ^b   Burroughs, L ^a,b   Englund, J A ^a,b,d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antiviral; CMV; Pediatric transplant; UL97 mutation

Indexed keywords

FOSCARNET; GANCICLOVIR;

ADOLESCENT; ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CHILD; CHRONIC MYELOID LEUKEMIA; CYTOMEGALOVIRUS INFECTION; FEMALE; GENE MUTATION; GRAFT RECIPIENT; HEART TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOPLASTIC LEFT HEART SYNDROME; IMMUNE DEFICIENCY; INFANT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; VIREMIA;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; GENE EXPRESSION REGULATION, VIRAL; HEART TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MUTATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 84871007310     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2012.00760.x     Document Type: Article

References (32)

1. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003; 9 (9): 543-558.
2. Torres-Madriz G, Boucher HW. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis 2008; 47 (5): 702-711.
3. Bueno J, Ramil C, Green M. Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients. Paediatr Drugs 2002; 4 (5): 279-290.
4. Biron KK, Fyfe JA, Stanat SC, et al. A human cytomegalovirus mutant resistant to the nucleoside analog 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl) guanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proc Natl Acad Sci U S A 1986; 83 (22): 8769-8773.
5. Erice A, Chou S, Biron KK, Stanat SC, Balfour HH Jr, Jordan MC. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989; 320 (5): 289-293.
6. Stanat SC, Reardon JE, Erice A, Jordan MC, Drew WL, Biron KK. Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrob Agents Chemother 1991; 35 (11): 2191-2197.
7. Blackman SC, Lurain NS, Witte DP, Filipovich AH, Groen P, Schleiss MR. Emergence and compartmentalization of fatal multi-drug-resistant cytomegalovirus infection in a patient with autosomal-recessive severe combined immune deficiency. J Pediatr Hematol Oncol 2004; 26 (9): 601-605.
8. Boeckh M, Huang M, Ferrenberg J, et al. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol 2004; 42 (3): 1142-1148.
9. Dykewicz CA. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: focus on community respiratory virus infections. Biol Blood Marrow Transplant 2001; 7 (Suppl): 19S-22S.
10. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface. Bone Marrow Transplant 2009; 44 (8): 453-455.
11. Castor J, Cook L, Corey L, Jerome KR. Rapid detection directly from patient serum samples of human cytomegalovirus UL97 mutations conferring ganciclovir resistance. J Clin Microbiol 2007; 45 (8): 2681-2683.
12. Eckle T, Lang P, Prix L, et al. Rapid development of ganciclovir-resistant cytomegalovirus infection in children after allogeneic stem cell transplantation in the early phase of immune cell recovery. Bone Marrow Transplant 2002; 30 (7): 433-439.
13. Boivin G, Goyette N, Gilbert C, Humar A, Covington E. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl Infect Dis 2005; 7 (3-4): 166-170.
14. Li F, Kenyon KW, Kirby KA, Fishbein DP, Boeckh M, Limaye AP. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. Clin Infect Dis 2007; 45 (4): 439-447.
15. Lurain NS, Bhorade SM, Pursell KJ, et al. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J Infect Dis 2002; 186 (6): 760-768.
16. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356 (9230): 645-649.
17. Patel SR, Ridwan RU, Ortin M. Cytomegalovirus reactivation in pediatric hemopoietic progenitors transplant: a retrospective study on the risk factors and the efficacy of treatment. J Pediatr Hematol Oncol 2005; 27 (8): 411-415.
18. Hantz S, Garnier-Geoffroy F, Mazeron MC, et al. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J Antimicrob Chemother 2010; 65 (12): 2628-2640.
19. Chou S. Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. Antimicrob Agents Chemother 2010; 54 (6): 2371-2378.
20. Gilbert C, Bestman-Smith J, Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat 2002; 5 (2): 88-114.
21. Chou S, Waldemer RH, Senters AE, et al. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis 2002; 185 (2): 162-169.
22. Chou S, Van Wechel LC, Lichy HM, Marousek GI. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob Agents Chemother 2005; 49 (7): 2710-2715.
23. Zhou L, Fan J, Zheng SS, Ma WH. Prevalence of human cytomegalovirus UL97 D605E mutation in transplant recipients in China. Transplant Proc 2006; 38 (9): 2926-2928.
24. Ijichi O, Michel D, Mertens T, Miyata K, Eizuru Y. GCV resistance due to the mutation A594P in the cytomegalovirus protein UL97 is partially reconstituted by a second mutation at D605E. Antiviral Res 2002; 53 (2): 135-142.
25. Erice A. Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev 1999; 12 (2): 286-297.
26. Jabs DA, Martin BK, Forman MS, et al. Mutations conferring ganciclovir resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis 2001; 183 (2): 333-337.
27. Eckle T, Prix L, Jahn G, et al. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood 2000; 96 (9): 3286-3289.
28. Sia IG, Wilson JA, Groettum CM, Espy MJ, Smith TF, Paya CV. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000; 181 (2): 717-720.
29. Humar A, Kumar D, Boivin G, Caliendo AM. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002; 186 (6): 829-833.
30. Ghisetti V, Barbui A, Franchello A, et al. Quantitation of cytomegalovirus DNA by the polymerase chain reaction as a predictor of disease in solid organ transplantation. J Med Virol 2004; 73 (2): 223-229.
31. Drew WL. Is combination antiviral therapy for CMV superior to monotherapy? J Clin Virol 2006; 35 (4): 485-488.
32. Trofe J, Pote L, Wade E, Blumberg E, Bloom RD. Maribavir: a novel antiviral agent with activity against cytomegalovirus. Ann Pharmacother 2008; 42 (10): 1447-1457.